ECDC/EMCDDA report: Evidence for the effectiveness of interventions to prevent infections among people who inject drugs. Part 1
Part 1: Needle and syringe programmes and other interventions for preventing hepatitis C, HIV and injecting risk behaviour
This is the first of two technical reports that present the evidence behind the Guidance on the prevention and control of infectious diseases among people who inject drugs.
The evidence presented here focuses on the effectiveness (and in some cases the cost-effectiveness) of the following interventions: the provision of needles and syringes; the provision of other (non-needle and syringe) drug preparation equipment; the provision of foil to stimulate route transition; the provision of information, education and counselling; knowledge of hepatitis C status; disease treatment; modes of service delivery including supervised injecting facilities; and access to, retention in, and combination of interventions.
Additional evidence on the effectiveness of drug treatment is covered in a companion technical report ‘Evidence for the effectiveness of interventions to prevent infections among people who inject drugs, Part 2: Drug treatment for preventing hepatitis C, HIV and injecting risk behaviour’.
Proficiency test for Listeria monocytogenes whole genome assembly 2018
16 May 2019 - This report presents the results of a proficiency test to evaluate the inter-laboratory reproducibility and portability of Listeria monocytogenes (Lm) genome assemblies in the EU/EEA.
ECDC strategic framework for the integration of molecular and genomic typing into European surveillance and multi-country outbreak investigations
4 Apr 2019 - This strategic framework document presents a proposed list of priority pathogens/diseases and outlines technical implementation options for the medium-term integration (2019–2021) of molecular/genomic typing information into EU-level surveillance and multi-country outbreak investigations.
Public consultation on HPV vaccines guidance opens
1 Apr 2019 - This guidance covers the following areas in relation to HPV vaccination: efficacy of the nine-valent HPV vaccine, HPV vaccination in people living with HIV and HPV vaccination in males and the cost-effectiveness of extending the HPV vaccination programme to include males.